Literature DB >> 7611661

The post-polio syndrome as an evolved clinical entity. Definition and clinical description.

M C Dalakas1.   

Abstract

Post-polio syndrome (PPS) refers to the new neuromuscular symptoms that occur at least 15 years after stability in patients with prior acute paralytic polio-myelitis. They include: (1) new muscle weakness and atrophy in the limbs, the bulbar or the respiratory muscles [post-poliomyelitis muscular atrophy (PPMA)] and (2) excessive muscle fatigue and diminished physical endurance. PPS is a clinical diagnosis that requires exclusion of all other medical, neurological, orthopedic or psychiatric diseases that could explain the cause of the new symptoms. Routine electromyography is useful to confirm chronic and ongoing denervation and exclude neuropathies. Muscle biopsy, single fiber electromyography (EMG), macro-EMG, serum antibody titers to polio virus, and spinal fluid studies are very useful research tools but they are rarely needed to establish the clinical diagnosis. PPS is a slowly progressive phenomenon with periods of stability that vary from 3 to 10 years. Current evidence indicates that PPS is the evolution of a subclinically ongoing motor neuron dysfunction that begins after the time of the acute polio. It is clinically manifested as PPS when the well-compensated reinnervating process crosses a critical threshold beyond which the remaining motor neurons cannot maintain the innervation to all the muscle fibers within their motor unit territory.

Entities:  

Mesh:

Year:  1995        PMID: 7611661     DOI: 10.1111/j.1749-6632.1995.tb27532.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  17 in total

1.  Factors contributing to preferential motor reinnervation in the primate peripheral nervous system.

Authors:  R D Madison; S J Archibald; R Lacin; C Krarup
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

Review 2.  Neurology and orthopaedics.

Authors:  Henry Houlden; Paul Charlton; Dishan Singh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03       Impact factor: 10.154

3.  Contrasting roles for axonal degeneration in an autoimmune versus viral model of multiple sclerosis: When can axonal injury be beneficial?

Authors:  Ikuo Tsunoda; Tomoko Tanaka; Emily Jane Terry; Robert S Fujinami
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

4.  Poliovirus-induced apoptosis is reduced in cells expressing a mutant CD155 selected during persistent poliovirus infection in neuroblastoma cells.

Authors:  Anne-Sophie Gosselin; Yannick Simonin; Florence Guivel-Benhassine; Vincent Rincheval; Jean-Luc Vayssière; Bernard Mignotte; Florence Colbère-Garapin; Thérèse Couderc; Bruno Blondel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Persistent poliovirus infection of human fetal brain cells.

Authors:  N Pavio; M H Buc-Caron; F Colbère-Garapin
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  [Postpolio syndrome. Neurologic and psychiatric aspects].

Authors:  M-A Weber; P Schönknecht; J Pilz; B Storch-Hagenlocher
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

7.  Update on current and emerging treatment options for post-polio syndrome.

Authors:  Elisabeth Farbu
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

8.  Outcomes of dual mobility articulation total hip arthroplasty in ipsilateral residual poliomyelitis.

Authors:  Teng-Feng Zhuang; Song-Wei Huan; Si-Min Luo; Guo-Rong She; Wen-Rui Wu; Jun-Yuan Chen; Ning Liu; Zhen-Gang Zha
Journal:  Int Orthop       Date:  2021-09-27       Impact factor: 3.075

9.  Role of medical rehabilitation in postpoliomyelitis syndrome. A case report.

Authors:  Gabriela Bombonica Dogaru; Ioana Stănescu
Journal:  Clujul Med       Date:  2013-05-09

10.  Vaccine-derived poliomyelitis and postpolio syndrome: an Italian Cutter Incident.

Authors:  Elena Angela Lusi; Paolo Guarascio
Journal:  JRSM Open       Date:  2014-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.